本文作者:李笑寅 减肥药大战升级!高盛预测口服减肥药将抢占三分之一市场份额,礼来领跑。 据追风交易台消息,高盛分析师Asad Haider、James Quigley等在其最新发布的研报中表示,口服GLP-1减肥药将成为生物制药领域最重要的新产品周期之一。 高盛预计,到2030/2035年,日服口服药片将占据减肥药(AOM)市场24%/32%的份额,市场规模达223亿/381亿美元,而礼来公司将...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.